Poster Abstracts • OFID 2018:5 (Suppl 1) • S567 with JNJ-8678 appeared to reduce VL more rapidly than PBO (figure). Median change in VL from baseline (BL) in JNJ-8678-treated patients (combined dose groups) vs. PBO was −1.98 vs. −0.32 log 10 copies/mL at Day 3. Mean differences in change from BL (90% CI) of JNJ-8678 (combined dose groups) vs. PBO on Days 2 and 3 were estimated −1.33 (−2.26; −0.39) and −1.62 (−2.55; −0.69) log 10 copies/mL, respectively (general linear model, adjusted for BL VL; P ≤ 0.05). There was a clear separation between JNJ-8678 and PBO, but no evident exposure-response relationship. JNJ-8678 was generally well tolerated with no new safety signals compared with adults and no dose relationship with AEs or lab abnormalities were observed.
Background. CSE, a novel combination of Ceftriaxone, Sulbactam and Disodium EDTA (Class 1 Antibiotic Resistance Breaker), is being developed for the treatment of patients with serious Gram-negative infections and has completed a Phase-3 clinical trial (NCT03477422) for treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). It restores and enhances the in vitro activity of Ceftriaxone against various β-lactamases (BLs), including enzyme families that belong to Ambler class A (TEM, SHV, CTX-M), class B (NDM, VIM, IMP), class C (some variants of AmpC), and class D {OXA extended spectrum BLs (ESBLs)}. This analysis was performed to assess the clinical and microbiological outcomes in patients infected with Ceftriaxone non-susceptible (C-NS), MDR and ESBL-producing Gram-negative pathogens at baseline.
Methods. Patients were randomized 1:1 to receive either CSE (1g Ceftriaxone/500 mg Sulbactam/37 mg EDTA) every 12 hours or Meropenem (MR) 1 g every 8 hours as 30 minutes IV infusion for 5-14 days. Oral step-down therapy was not allowed. Biological specimens were analyzed, and resistant pathogens identified. MDR was defined as resistance to at least three categories of antimicrobials. Identification of pathogens and antibiotic susceptibility testing were performed and interpreted according to Clinical and Laboratory Standards Institute methodologies. Combined Disc Diffusion Test was used to detect ESBL-production in pathogens.
Results. Of 230 randomized patients, 143 (62.2%) were included in m-MITT [72/74 (97. 3) in CSE and 68/69 (98.6%) in MR groups had C-NS pathogens; 63/74 (85.1%) in CSE and 56/69 (81.2%) in MR groups had ESBL-producing pathogens; 55/74 (74.3%) in CSE and 45/69 (65.2%) in MR group had MDR pathogens]. Mean duration of IV therapy was 7 days. The clinical cure and microbiological eradication rates for CSE and MR at the test of cure (TOC) visit in C-NS, ESBL and MDR pathogens is shown in Figures 1, 2, and 3 , respectively.
Conclusion. At TOC, clinical cure and microbiological eradication rates were higher for CSE as compared with MR across all three analyses sets. Overall, CSE was effective in the treatment of patients with cUTI and AP caused by resistant Gramnegative pathogens.
Background. Penicillin allergy is reported in 10% patients in the US Patients with penicillin allergies are treated with broader spectrum antibiotics, often leading to more antibiotic-resistant infections, including C. difficile, increased risk of surgical site infections, and increased healthcare costs.
Methods. After informed consent, Medical-Surgical patients with documented allergies to penicillin (P) or cephalosporins (C) were given challenge doses through a standardized 2-step protocol from June 2015 to November 2017 at our community hospital. Patients with documented IgE-mediated hypersensitivity (HSR), rash or unknown reactions were eligible. Those with anaphylaxis or Type II-IV HSR were excluded. Treating clinicians selected the antibiotic for testing guided by the protocol: 323/336 patients (96%) were challenged with C. Based on results, allergies were updated in patients' charts, noting that tolerance of cephalosporins does not preclude penicillin allergy. Charts were reviewed to determine adverse events and antibiotic narrowing, the latter adjudicated by ID specialists not directly involved in the patient's care. A cost analysis used the acquisition cost of administered antibiotics before and after testing.
Results. 336 patients (53 Medical, 283 Surgical) underwent the allergy test dose protocol: 267 with reported P allergy, 47 C allergy, 22 P+C allergy. None had a major adverse reaction. 7 patients (2%) experienced minor reactions: rash (4), throat irritation (1), urticaria (1), wheezing (1). Before testing, 321/336 were prescribed inappropriate or broad antibiotics. After challenge dose testing, the antibiotic spectrum was narrowed in 308/321 (96%). The total Pharmacy cost savings was $38,281.00 with the optimized antibiotic regimen, translating to $630 saved per patient. In Surgical patients there was a 50% cost savings.
Conclusion. Despite the frequency with which β-lactam allergies are reported, few patients had an allergy that interfered with optimal treatment when tested. This standardized protocol can be safely performed in a community hospital setting and lead to improved antibiotic choice and pharmacy cost savings. 
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